BLINATUMOMAB

Brand name:

• Blincyto®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Measurable residual disease (MRD)-negative B-cell precursor acute lymphoblastic leukaemia (B-ALL)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to listing (Matters arising/Matters outstanding)

Comment:

--

Submission sponsor:

AMGEN AUSTRALIA PTY LIMITED

Other PBAC consideration:

• BLINATUMOMAB

Submission received for:

November 2024 PBAC meeting

Opportunity for consumer comment:

Open 31/07/2024 and close 25/09/2024 (see PBS Website)

PBAC meeting:

Held on 06/11/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

04/12/2024

Lodgement of required documentation:

11/12/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 21/01/2025

Status:

Finalised

Government processes:

Commenced on 21/01/2025

Medicine listed on the PBS:

01/03/2025 (see PBS schedule)

---